PREVENIR-IVF: study protocol for a prospective multicentre randomized open comparative trial, which explores the efficacy of a multidisciplinary platform reducing and preventing reprotoxic environmental exposures in subfertile couples on live birth rate after assisted reproduction treatment Authors: Claire Sunyach, Blandine Courbiere, Nicolas Simon, Fleur Delva, Ronan Garlantezec, Florence Bretelle, Roger Leandri, Jean-François Gehanno, Yolande Esquirol, Sandrine Loubiere, Noémie Resseguier, Irène Sari-Minodier, Jeanne Perrin Published: 2025 ABSTRACT BackgroundA growing body of research suggests that parental exposure to environmental exposures (chemical, physical, organizational, stress) or abnormal body mass index (BMI) may impair couples’ reproductive health. In many couples, these exposures in the workplace, at home (notably addictions, diet and physical activity) or in the domestic environment (stress, chemical and/or physical exposures) can be mitigated or eliminated by protective measures or by promoting behavioural changes. We postulate that in subfertile couples starting assisted reproduction treatment (ART), the systematic use of a multidisciplinary support platform aimed at detecting all environmental risk factors and implementing personalized preventive/corrective measures will improve ART outcomes and the spontaneous pregnancy rate.MethodsOn the basis of the French PREVENIR (PREVention ENvIronment Reproduction) platform network, we designed a prospective multicentre randomized open-label comparative study in 2112 subfertile couples eligible for in vitro fertilization (IVF). The primary objective is to evaluate the efficiency of using the PREVENIR platform before the first IVF/ICSI (“platform pathway”, arm A) compared with standard ART without the PREVENIR platform (“standard pathway”, arm B) by comparing the proportions of couples who obtain at least one live birth during the 24 months of follow-up. Patients will complete four self-report questionnaires assessing environmental exposures, quality of life, physical activity and mental health. BMI and exhaled CO will be measured at inclusion, during IVF/ICSI and then every 6 months for 24 months. IVF/ICSI and pregnancy data will be registered. In arm A, free teleconsultations with dieticians, addictologists, psychologists and occupational physicians will be provided if necessary, and an application will be used for personalized patient information. A cost-effectiveness study will inform the public health stakeholders on the relevance of implementing such a platform.DiscussionThe PREVENIR-IVF protocol addresses environmental exposures in a holistic manner, with a strong focus on occupational exposures. Spontaneous and/or post-ART birth rate, time to pregnancy and the course of pregnancies could be improved in “platform” versus “standard” pathway. From a public health and social point of view, professional health networks such as PREVENIR would contribute to health education by raising awareness of the environmental challenges to reproductive health.Trial registrationClinicalTrials NCT06100523. Registered on 2023 October 25.Supplementary InformationThe online version contains supplementary material available at 10.1186/s13063-025-09208-8. Introduction Background Approximately, 17% of couples (17.8% in high-income countries and 16.5% in low- and middle-income countries) consult a physician during their reproductive life for an unfulfilled desire for pregnancy [39]. This pathology affects one in six couples and represents a growing public health concern in European countries [75]. Numerous studies have demonstrated the deleterious effects of environmental exposures to reprotoxic behavioural (tobacco, alcohol, cannabis or being overweight), domestic (chemicals including endocrine disruptors [EDs] or pesticides) and/or occupational (i.e. EDs, metals, solvents, pesticides, polycyclic aromatic hydrocarbons [PAHs], physical agents including heat and vibration for men) factors on female and male fertility [78]. Several clinical studies have demonstrated the positive effects of improving parental environmental factors on the chances of pregnancy in in vitro fertilization (IVF) and on pregnancy outcomes, such as smoking cessation, weight loss (for obese patients), regular physical exercise, stress and anxiety reduction, and lifestyle modification programmes [36, 43, 47]. A modelling analysis has suggested a beneficial impact of these interventions on infertility treatment costs and outcomes [65]. Nevertheless, a Cochrane review has highlighted the “need for high-quality randomized controlled trials to investigate preconception lifestyle advice on a combination of topics” in subfertile couples [7]. Since 2013, the reduction in reprotoxic environmental exposures during the preconception period in women and men has been the subject of recommendations from several international and national societies and public health organizations. This position has most recently been reiterated by the European Society for Human Reproduction and Embryology [26]. However, this practice is currently unevenly utilized in fertility centres. Environmental and behavioural dimensions are among the causes of the alterations in certain parameters of reproductive health. Thus, lifestyle, habits and occupation lead to passive or active exposure to environmental toxins [2, 5], and occupation is also a source of reprotoxic exposure. Behavioural exposures It is now well recognized that lifestyle impacts reproductive health. Behavioural exposures include inappropriate dietary patterns and poor-quality diets, leading to individuals being over- or underweight. The relationships between weight and/or body mass index (BMI, defined as the ratio of body mass to height2), food quality and male reproduction have thus been studied [24, 58]. Females being overweight are also associated with an increased risk of infertility [79]. In addition, poor-quality diets and sedentary lifestyles may be associated with infertility. Some observational studies have suggested that male and female fertility could benefit from moderate physical activity, and that sedentary behaviour is correlated with male and female infertility [28, 30, 50]. In addition to poor diet and low physical activity, addiction (tobacco, alcohol and drug use) and stress are modifiable factors that should be considered. Thus, the consequences of active smoking and alcohol consumption have also been studied in both males and females [20]. In addition, regular cannabis use in men affects semen parameters and sperm DNA methylation [34, 59] and is also a likely aggravating cofactor of preexisting spermatogenesis disorders [5]. In females, cannabis use and the endocannabinoid system affect the reproductive system, including ovulation, tubal transport and placentation [10]. Stress can also negatively impact male fertility through the degradation of semen parameters [33]. In females, stress has been suggested to increase the time to pregnancy (TTP) [51], accelerate ovarian reserve exhaustion [6] or decrease anti-Mullerian hormone levels [77] in young women. Occupational exposures The workplace is a major source of exposure to chemical and physical agents with a reprotoxic effect, particularly PAHs, endocrine disruptors, pesticides, metals, and solvents [31, 37, 63, 74]. For men, this is mainly the case for industrial, plastic, and public workers (who are exposed to bitumen fumes). Exposure to phthalates, solvents, certain pesticides, and heat or vibration can lead to sperm abnormalities and/or spermatogenesis alteration [25]. The main occupations that are significantly associated with altered sperm parameters are blue-collar workers such as painters, farmers, welders, plumbers, and technicians [53]. Female workers at higher infertility risk work, for example, as hairdressers, beauticians, cleaners, or maintenance workers. The associations between reproductive disorders and exposure to cosmetic products in these professions were determined by INRS (The French National Research and Safety Institute for the Prevention of Occupational Accidents and Diseases) and ANSES (French Agency for Food, Environmental and Occupational Health and Safety) in 2014 and in several meta-analyses and systematic reviews [4, 42, 54, 71]. Domestic exposures Numerous exposures to reprotoxic compounds result from daily domestic habits, mainly through consumer products. Poor-quality domestic air pollutants resulting from secondhand smoke, biomass fuel smoke, and organic solvents are also linked to delayed time to pregnancy [62] and adverse birth outcomes [35, 73]. Disruption of the endocrine system accounts for potential mechanisms for these adverse effects [18]. Commonly used consumer products (e.g. cleaning products) can expose individuals to various reprotoxic agents, such as endocrine disruptors, pesticides, metals and solvents. Vabre and colleagues reported the involvement of environmental factors in the occurrence of early ovarian insufficiency [71]. Interestingly, in contrast to outdoor air pollution, indoor air quality can be significantly improved by simple daily changes in the home or at the workplace. Similarly, modification of daily beauty routines could improve female fertility by decreasing the phthalate concentration in follicular fluids [55]. Moreover, short educational interventions successfully alter biomarker concentrations of phenols, glycol ethers and phthalates resulting from dietary intake and personal care product (PCP) use [76]. The various types of risk factors for fertility disorders are not mutually exclusive. Therefore, reducing environmental exposure requires multidisciplinary cooperation. Infertility problems and ART affect couples both physically and psychologically, particularly when the process ends in failure or lasts several years [14, 56]. Moreover, from a societal point of view, these treatments are costly and impose a burden on the health care system and on the patients. Effort must be made to increase the chances of obtaining a live birth as soon as possible and in a cost-effective way. Overall, a growing body of research suggests that parental exposure to environmental toxins poses a risk to the reproductive health of couples. While scientific evidence is incomplete or not always conclusive [7], there is a clear link between the presence of numerous toxic substances and subfertility. Some environmental causes are difficult to modify at the individual level (e.g. air pollution). However, some of these exposures can be mitigated or eliminated by protective measures in the workplace or at home by promoting changes in behaviour (smoking cessation, weaning off cannabis, rebalancing diet or reducing consumption of ultra-processed industrial products). We postulate that including the identification of environmental risk factors into the assisted reproduction technique (ART) process, together with implementing preventive and corrective measures, will improve ART outcomes and the spontaneous pregnancy rate between ART cycles. To increase the chances of birth, we propose the systematic use of a multidisciplinary support platform for subfertile couples aimed at detecting environmental risk factors (including BMI, diet, smoking, cannabis use and exposure to domestic and occupational environmental pollutants) and implementing personalized preventive or corrective measures. Objectives and outcomes Primary objective The primary objective is to evaluate the efficacy of managing subfertile couples by a multidisciplinary platform that considers environmental, occupational and behavioural factors (“platform pathway”, arm A) compared with the standard assisted reproductive technique (ART) pathway (“standard pathway”, arm B) by comparing the proportions of couples who obtain at least one live birth during the 24 months of follow-up (pregnancies obtained by ART and/or spontaneously). Secondary objectives The secondary objectives are as follows: (1) To evaluate the impact of multidisciplinary platform management on IVF/ICSI biological parameters, cumulative clinical and ongoing pregnancy rates (post-ART or spontaneous), pregnancy outcomes (post-ART or spontaneous), newborn health and reprotoxic behaviours of couples, (2) to analyse the barriers and levers to patients’ adherence to the preventive/corrective advice recommended during ART treatment (arms A and B), and (3) to assess the cost-effectiveness of setting up the platform in terms of the proportion of couples obtaining at least one live birth within 24 months, as well as the financial sustainability (budget impact analysis) of disseminating the innovation throughout the health care system. Methods Trial design The trial design included a prospective multicentre randomized open-label controlled trial evaluating the efficacy of an innovative personalized management strategy adapted to the level of environmental risk in a population of subfertile couples eligible for ART management by intraconjugal IVF/ICSI. The allocation ratio is 1:1, and the framework is superiority in parallel groups. The open design is imposed by the intervention implemented (access to a platform and use of an application); nevertheless, the main judgment criterion (live birth) is particularly objective. Centres Seven ART centres (Public University Hospitals of Marseille, Bordeaux, Toulouse, Rennes, Rouen and Creteil and Private St Joseph Hospital of Marseille, France) will enroll couples, which will be managed by six PREVENIR multidisciplinary platforms. The PREVENIR platforms are located in reproductive medicine centres (Marseille, Toulouse and Rouen) or Regional Centres of Occupational and Environmental Pathologies (CRPPE) (Bordeaux, Rennes and Creteil) in Public University Hospitals. These platforms bring together midwives, nurses, health and environment engineers and physicians specializing in occupational health, public health and reproductive health, all of whom are trained for detection and counselling regarding environmental reprotoxicants. The study centres required a PREVENIR platform and an associated clinical-biological ART centre. We included all the platforms of the PREVENIR network at the time of protocol submission, regardless of the number of IVF cycles performed annually in their associated ART centres. All ART centres are accredited by harmonized European standards: NF EN ISO 15189. Inclusion criteria The inclusion criteria are as follows: couples eligible for a first cycle of intraconjugal conventional in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI), signatures of informed consent by both partners in the couple and a smartphone/personal computer. Exclusion criteria The exclusion criteria are as follows: lack of language skills, refusal of one or both members of the couple to take part in the study, use of gametes banked before undergoing ART, gamete or embryo donation, history of chemotherapy/radiotherapy, complex synechia cure, uterine hypoplasia, receiving treatment in a viral risk circuit, not having a smartphone and not having social security. Enrolment and assignment of interventions In couples eligible for a first intraconjugal IVF/ICSI treatment, participation in the PREVENIR-IVF project will be proposed by the gynaecologist, the embryologist or authorized surrogates, during a couple visit at the fertility centre. Potential participants will be identified in the patients’ list, and a reminder will be sent to clinicians/embryologists before the consultation. No public advertisement is planned. The initial contact will be made by doctors; motivation for participation will be a 50% chance to benefit from personalized free environmental follow-up in order to improve the live birth rate. The timeline for recruitment is 88 couples per month during 24 months. Couples who sign the consent form will be included and randomized (“platform pathway”, arm A vs. “standard pathway”, arm B) (Fig. 1). The randomization list will be established before the implementation of the study in a 1:1 ratio, using permutation blocks of variable size but a multiple of 2 (maximum 8). A randomization list will be established for each investigating centre (stratification by centre). No stratification criteria other than the centre will be used. The sequence will be generated by the clinical research assistant, through the electronic case report form (e-CRF) (REDCap®, Vanderbilt University, TN, USA). REDCap® is the mechanism for implementing the allocation sequence and ensuring its concealment. The gynaecologist/embryologist will enroll participants, and they will be assigned automatically by the electronic system, based on the sequence.Fig. 1Flowchart of PREVENIR-IVF protocol. , hair sampling; , weighing; and , exhaled CO measurement Flowchart of PREVENIR-IVF protocol. , hair sampling; , weighing; and , exhaled CO measurement Interventions Each patient will complete four standardized online self-report questionnaires assessing lifestyle factors (including environmental and occupational exposures), quality of life, physical activity and mental health as follows:The PREVENIR questionnaire was designed to assess reprotoxic exposure from lifestyle, diet, domestic and workplace (supplementary data 1), including occupational stress via a 1–10 analogue scale. It was designed by the PREVENIR platforms, based on publications of the consortium using standardized questionnaires [19, 21, 22, 67].The FertiQoL questionnaire was previously developed to assess the quality of life of men and women experiencing fertility problems using a 100 score [8]. It Has been adapted in numerous languages around the world and is internationally benchmarked [29]. Since inception, the reliability of the FertiQoL instrument across gender and diverse infertile populations experiencing different infertility treatments Has been well documented [23, 60, 64, 72]. The PREVENIR questionnaire was designed to assess reprotoxic exposure from lifestyle, diet, domestic and workplace (supplementary data 1), including occupational stress via a 1–10 analogue scale. It was designed by the PREVENIR platforms, based on publications of the consortium using standardized questionnaires [19, 21, 22, 67]. The PREVENIR questionnaire was designed to assess reprotoxic exposure from lifestyle, diet, domestic and workplace (supplementary data 1), including occupational stress via a 1–10 analogue scale. It was designed by the PREVENIR platforms, based on publications of the consortium using standardized questionnaires [19, 21, 22, 67]. The FertiQoL questionnaire was previously developed to assess the quality of life of men and women experiencing fertility problems using a 100 score [8]. It Has been adapted in numerous languages around the world and is internationally benchmarked [29]. Since inception, the reliability of the FertiQoL instrument across gender and diverse infertile populations experiencing different infertility treatments Has been well documented [23, 60, 64, 72]. The FertiQoL questionnaire was previously developed to assess the quality of life of men and women experiencing fertility problems using a 100 score [8]. It Has been adapted in numerous languages around the world and is internationally benchmarked [29]. Since inception, the reliability of the FertiQoL instrument across gender and diverse infertile populations experiencing different infertility treatments Has been well documented [23, 60, 64, 72]. The Hospital Anxiety and Depression (HAD) questionnaire was developed to assess depression and anxiety troubles [80] by 2 scores, each calculated out of 20. The HaDS Has been widely used to assess anxiety and depression symptoms in patients suffering from various health problems, i.e. cancer [3] and human immunodeficiency virus [9], and Has also been applied to men and women facing infertility [40, 41, 48].The short version of the International Physical Activity Questionnaire (IPAQ) was developed for providing the time spent in vigorous- and moderate-intensity activity and in sedentary activity [15, 16] by a classification as “low”, “intermediate” or “high” intensity physical activity. This questionnaire Has been validated in several countries and used to investigate the benefice of physical activity in a variety of fertility and gestational complications ranging from polycystic ovary syndrome [61], gestational diabetes mellitus [1, 70] and pregnancy loss [57]. Short version decreases the burden of completion and decreases memorization bias. The Hospital Anxiety and Depression (HAD) questionnaire was developed to assess depression and anxiety troubles [80] by 2 scores, each calculated out of 20. The HaDS Has been widely used to assess anxiety and depression symptoms in patients suffering from various health problems, i.e. cancer [3] and human immunodeficiency virus [9], and Has also been applied to men and women facing infertility [40, 41, 48]. The Hospital Anxiety and Depression (HAD) questionnaire was developed to assess depression and anxiety troubles [80] by 2 scores, each calculated out of 20. The HaDS Has been widely used to assess anxiety and depression symptoms in patients suffering from various health problems, i.e. cancer [3] and human immunodeficiency virus [9], and Has also been applied to men and women facing infertility [40, 41, 48]. The short version of the International Physical Activity Questionnaire (IPAQ) was developed for providing the time spent in vigorous- and moderate-intensity activity and in sedentary activity [15, 16] by a classification as “low”, “intermediate” or “high” intensity physical activity. This questionnaire Has been validated in several countries and used to investigate the benefice of physical activity in a variety of fertility and gestational complications ranging from polycystic ovary syndrome [61], gestational diabetes mellitus [1, 70] and pregnancy loss [57]. Short version decreases the burden of completion and decreases memorization bias. The short version of the International Physical Activity Questionnaire (IPAQ) was developed for providing the time spent in vigorous- and moderate-intensity activity and in sedentary activity [15, 16] by a classification as “low”, “intermediate” or “high” intensity physical activity. This questionnaire Has been validated in several countries and used to investigate the benefice of physical activity in a variety of fertility and gestational complications ranging from polycystic ovary syndrome [61], gestational diabetes mellitus [1, 70] and pregnancy loss [57]. Short version decreases the burden of completion and decreases memorization bias. In arm A (“platform pathway”), couples will be followed up via the multidisciplinary PREVENIR platform according to the analysis of initial self-questionnaires. An additional interview will be provided by a nurse or a midwife trained in environmental and occupational health upon missing information and/or suspicion of occupational reprotoxic exposure. The interview template and guidelines will be available for each centre (supplementary data 2). Teleconsultation (TCS) with a dietician will be scheduled if a participant has a BMI > 25. TCS with an addictologist will be provided for reported weekly consumption of alcohol (> 12 units per week; 1 unit of alcohol = 1 glass = 10 g), tobacco, cannabis, other drugs, or other addictions impacting the couple (i.e. compulsive use of social media, video games, pornography, gambling). TCS with a psychologist will be proposed if anxiety and/or depression scores (HADs) are > 10/20 and if the occupational stress score is > 6/10 and/or upon patient request. The providers of TCS (dieticians, addictologists and psychologists) are qualified liberal practitioners, experienced in perinatal health. In addition, in arm A, a mobile application dedicated to the project (HOPPEN, 35510 Cesson Sévigné, France) will be used to prepare the follow-up of patients requiring intervention by professionals (dieticians, addictologists or psychologists) via complementary questionnaires. Each patient will also find information in the APP, including information on diet, daily exposure to toxins and chemical products (e.g. endocrine disruptors in cosmetics and daily products) and occupational exposures. The PREVENIR platform team will then synthesize reprotoxic exposures of both members of the couple during a multidisciplinary consultation meeting (MCM). A meeting report will specify the hierarchized preventive and corrective measures to be implemented, including specific advice and specialized treatment if necessary. The personalized measures decided by the MCM will be provided to the couple through a TCS, including information on the personalized care strategy proposed (addictologist follow-up, dietician, psychologist or occupational physician), and personalized advice sheets will be explained. The personalized advice sheet includes two tables: one summarizes the reprotoxic exposures identified or suspected in woman and man (lifestyle, BMI, physical activity, scores of anxiety and depression, occupational exposures and stress level, domestic exposures including exposures to ED and lead in air/water/food packaging), and one gives hierarchical advice to woman and to man (personalized upon exposures identified in the first table), including the proposed TCS (dietician, addictologist, psychologist, occupational physician). The two tables are followed by detailed comments on how to put the advice into practice and by complementary information and resources. The MCM conclusion report will be shared with the gynaecologist in charge of the couple. In arm B (“standard pathway”), couples will receive care according to the usual procedure of each clinical centre team (indications, network of practitioners, follow-up and information tools). An information leaflet about the impacts of the environment on fertility and how to protect themselves will be given to them. The first IVF/ICSI will be performed in both arms. During the month before the first IVF/ICSI, couples will complete the same four standardized online self-report questionnaires as at enrolment (assessing lifestyle factors, quality of life, physical activity and mental health). In both arms, after the first IVF/ICSI, couples will be followed for 24 months, and the four online self-questionnaires will be completed every 6 months, with additional questions about consumption of care during the previous months (psychologist/psychiatrist, dietician, addictologist, occupational physician, other) and health care expenses related to the ART pathway. In arm A (Fig. 1), during the 24 months of follow-up, active support for corrective measures implemented by the platform will be proposed with the help of the application (weight loss and diet objectives, changes in habits, physical activity and the reduction or cessation of toxic substances). Specialized follow-up by professionals (dieticians, addictologists and psychologists) via the TCS will continue if necessary: up to four TCS by patient are supported by the project, with a frequency adapted to the patient and the professional, on the period of the patient’s follow-up. Patients will be followed by the same professionals regardless of the ART centre they visit. During the study, a panel of 20 couples in each arm will be the subject of a semi-structured interview designed to qualitatively determine the obstacles and levers to their adherence to the environmental health advice received during their ART treatment. A health economic analysis is planned to assess the cost-effectiveness of the experimental platform compared to standard practice in order to inform decision-makers on its (economic) efficiency. In addition, a budget impact analysis (BIA) will focus on the expected changes in health system expenditures after the adoption of the new practice, once its efficiency is demonstrated. A medico analysis study will be performed by the Epidemiology and Health Economics Department of AP-HM, according to the more recent recommendations in health economics (ref.) [11, 49]. Criteria for discontinuing or modifying allocated interventions for a given trial participant were defined as follows: the intervention will be discontinued on the participant’s request or in case of separation of the couple, referral to gamete or embryo donation or death. Patients in “platform pathway” showing no adherence to the protocol (such as not completing questionnaires, not attending consultations) will not be discontinued, as long as information about their ART treatments, pregnancies and live birth can be obtained during the 24-month follow-up (intention to treat). Patients with spontaneous pregnancy (before the first or between ART treatments) will not be discontinued, since in “platform pathway” advice is given to patients during the 6 weeks following inclusion (though before the spontaneous pregnancy); moreover, the main objective of the study considers live births obtained after ART treatment or spontaneously. Filling out questionnaires or scheduling and attending specialized consultations can be tedious. Strategies to improve adherence to intervention protocols, as well as any procedures for monitoring adherence, must be implemented. The intervention of the PREVENIR-FIV project consists of systematizing and facilitating access to environmental care for subfertile patients, thanks to the platform aided by the use of an application. In the “platform pathway”, the application will be installed on demand by the clinical research assistant on patients’ smartphones during the inclusion consultation. When a professional follow-up is proposed to patients, patients will be called by the professionals to schedule a TCS (possibly scheduled outside working hours); standardized feedback of the first TCS will be sent by the professional to the platform and included in the e-CRF. The number of TCS for each patient will be registered in the e-CRF by the patients, and also by the principal investigator, upon billing of consultations to practitioners. If patients in the “platform pathway” refuse a professional follow-up, the reason will be registered. No changes in routine care of each centre is planned. Hence, in the “standard pathway”, prohibiting concomitant care to subfertile couples would not be ethical; that is why an information leaflet about the impacts of the environment on fertility and how to protect themselves will be given to them at inclusion. Couples in the “standard pathway” will be managed using the usual healthcare network of their clinician, which does not exclude addressing patients to a dietician/addictologist/psychologist when needed. Nevertheless, these consultations will need to be scheduled and paid for by the patients, with possible induced professional absenteeism, which is a major issue in the fertility care pathway and is known to generate low adherence. In the “standard” and “platform pathways”, all types of consultations received by patients and healthcare expenses will be registered every 6 months in the e-CRF. Strategy to promote participant retention and complete follow-up, including a list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols, is as follows: in case of nonresponse to auto-questionnaires, REDCap® will automatically send a reminder e-mail to patients after 48 h. If non-response persists, platform clinical research technicians of the platform will call the patients after 7 days. The strategies to keep participants engaged for the full 24-month follow-up are based on the following: a phone call from the platform to the patients before each questionnaire sending (every 6 months) and a personal contact with patients during weighing and expired CO measuring (every IVF/ICSI). Plans for data entry, coding, security and storage, including any related processes to promote data quality (e.g. double data entry, range checks for data values), are available in the protocol in paragraphs IX.A, XIII.C and XIII.D. Sample size and statistical analysis The project has an inclusion period of 24 months, and couples will be followed for 24 months from the first IVF/ICSI. The total duration of patient participation will be 30 months. The number of couples to be included in the study is estimated at 2112, i.e. 4224 patients, under the following assumptions: (i) an expected rate of couples having obtained at least one live birth over 24 months of 42.5% in arm B, (ii) an increase in this rate to 48.9% in arm A (+ 15%), (iii) balanced randomization (randomization ratio 1:1) and (iv) a two-sided alpha risk of 0.05 and a beta risk of 0.20 (i.e. a power of 0.80). The number of couples to be included is 950 per group, i.e. 1900 couples in total. The expected drop-out rate is 10%, which means that 2112 couples (4224 patients) must be recruited [12, 17, 27, 44, 46, 69]. For achieving target sample size enrolment, progression will be monitored and analysed each month by the coordination of the project and every 6 months by the steering committee. In case of insufficient sample size, corrective actions will be discussed and carried out. Trial conduct Any serious adverse event occurring during the investigations will be reported according to the internal procedure of each establishment. In case of minor events, such as emotional distress from the questionnaires, stress from lifestyle changes or any negative impact on the couple’s relationship, couples will report to the platform: a psychologist from the PREVENIR-IVF team could be assigned to provide support, and the report will be documented and sent to the principal investigator through the e-CRF. Data collection, management and analysis SPIRIT figure w, weeks; t1, before first IVF/ICSI; t2, first IVF/ICSI; t3, before each subsequent frozen embryo transfer or IVF/ICSI; t4, each subsequent frozen embryo transfer; t5, each subsequent IVF/ICSI; m, months; *after the first IVF/ICSI; t6, during pregnancy; t7, delivery w, weeks; t1, before first IVF/ICSI; t2, first IVF/ICSI; t3, before each subsequent frozen embryo transfer or IVF/ICSI; t4, each subsequent frozen embryo transfer; t5, each subsequent IVF/ICSI; m, months; *after the first IVF/ICSI; t6, during pregnancy; t7, delivery Outcome data All data obtained in the study will be registered pseudoanonymously in an e-CRF (REDCap®, Vanderbilt University, TN, USA) managed by the Clinical Research Service of Marseille University Hospitals. Pregnancies obtained by fresh or thawed embryo transfer or spontaneous pregnancies during the 24-month follow-up will be considered in the study. Primary and secondary endpoints will be compared in arm A and arm B. Primary endpoint The primary endpoint is the proportion of couples achieving at least one live birth during 24 months of follow-up (birth(s) achieved after IVF/ICSI [fresh or thawed embryo transfer] or spontaneously) in arm A versus arm B. It is calculated as the rate of couples achieving at least one live birth, which is the number of couples with at least one delivery of a living newborn > 22 weeks of gestation (WG) divided by the number of couples enrolled in the arm with a 24-month follow-up. Secondary endpoints The following secondary endpoints will be compared in arm A versus arm B and are calculated as follows: The fertilization rate is the number of zygotes showing two pronuclei (PN) 16–19 h after fertilization divided by the number of inseminated mature oocytes; the rate of transferable embryos is the number of embryos transferred or cryopreserved divided by the number of diploid embryos on days 2 or 3. The embryo implantation rate is the number of gestational sacs at 6 WG divided by the number of transferred embryos (fresh or thawed). The clinical pregnancy rate is the number of gestational sacs at 5 WG divided by the number of embryo transfers; the ongoing pregnancy rate is the number of gestational sacs with cardiac activity at 10 WG divided by the number of gestational sacs at 5 SW. The rate of obstetric pathology is the number of pregnancies with at least one of the following complications: gestational hypertension, pre-eclampsia, GDM, cholestasis, placenta previa, placental abruption, FGR, vanishing twin syndrome, PROM, TBL, 2nd and 3rd trimester haemorrhage, preterm delivery and PPH divided by the number of ongoing pregnancies. Newborn health will be described by term, sex, weight, height and major and minor malformations at birth. The behavioural changes will be assessed by comparing substance abuse, physical activity, eating habits, stress management and protection against environmental/occupational reprotoxins at enrolment versus at the subsequent steps of the PREVENIR, HAD and IPAQ questionnaires. The quality-of-life scores will be obtained via the FertiQOL questionnaires.The barriers and levers related to couples’ adherence to measures for preventing and correcting reprotoxic exposures proposed during their ART pathway will be assessed by a qualitative analysis based on interviews of a subgroup of the arms A and B.Cost-effectiveness endpoints are described in the “health economic analysis” paragraph. The fertilization rate is the number of zygotes showing two pronuclei (PN) 16–19 h after fertilization divided by the number of inseminated mature oocytes; the rate of transferable embryos is the number of embryos transferred or cryopreserved divided by the number of diploid embryos on days 2 or 3. The embryo implantation rate is the number of gestational sacs at 6 WG divided by the number of transferred embryos (fresh or thawed). The clinical pregnancy rate is the number of gestational sacs at 5 WG divided by the number of embryo transfers; the ongoing pregnancy rate is the number of gestational sacs with cardiac activity at 10 WG divided by the number of gestational sacs at 5 SW. The rate of obstetric pathology is the number of pregnancies with at least one of the following complications: gestational hypertension, pre-eclampsia, GDM, cholestasis, placenta previa, placental abruption, FGR, vanishing twin syndrome, PROM, TBL, 2nd and 3rd trimester haemorrhage, preterm delivery and PPH divided by the number of ongoing pregnancies. Newborn health will be described by term, sex, weight, height and major and minor malformations at birth. The behavioural changes will be assessed by comparing substance abuse, physical activity, eating habits, stress management and protection against environmental/occupational reprotoxins at enrolment versus at the subsequent steps of the PREVENIR, HAD and IPAQ questionnaires. The quality-of-life scores will be obtained via the FertiQOL questionnaires. The fertilization rate is the number of zygotes showing two pronuclei (PN) 16–19 h after fertilization divided by the number of inseminated mature oocytes; the rate of transferable embryos is the number of embryos transferred or cryopreserved divided by the number of diploid embryos on days 2 or 3. The embryo implantation rate is the number of gestational sacs at 6 WG divided by the number of transferred embryos (fresh or thawed). The clinical pregnancy rate is the number of gestational sacs at 5 WG divided by the number of embryo transfers; the ongoing pregnancy rate is the number of gestational sacs with cardiac activity at 10 WG divided by the number of gestational sacs at 5 SW. The rate of obstetric pathology is the number of pregnancies with at least one of the following complications: gestational hypertension, pre-eclampsia, GDM, cholestasis, placenta previa, placental abruption, FGR, vanishing twin syndrome, PROM, TBL, 2nd and 3rd trimester haemorrhage, preterm delivery and PPH divided by the number of ongoing pregnancies. Newborn health will be described by term, sex, weight, height and major and minor malformations at birth. The behavioural changes will be assessed by comparing substance abuse, physical activity, eating habits, stress management and protection against environmental/occupational reprotoxins at enrolment versus at the subsequent steps of the PREVENIR, HAD and IPAQ questionnaires. The quality-of-life scores will be obtained via the FertiQOL questionnaires. The barriers and levers related to couples’ adherence to measures for preventing and correcting reprotoxic exposures proposed during their ART pathway will be assessed by a qualitative analysis based on interviews of a subgroup of the arms A and B. The barriers and levers related to couples’ adherence to measures for preventing and correcting reprotoxic exposures proposed during their ART pathway will be assessed by a qualitative analysis based on interviews of a subgroup of the arms A and B. Cost-effectiveness endpoints are described in the “health economic analysis” paragraph. Cost-effectiveness endpoints are described in the “health economic analysis” paragraph. Exposure data To assess potential toxicant exposure and the extent of lifestyle modification, the following data and biological samples will be collected at enrolment, before the first IVF/ICSI and 12 months after the first IVF/ICSI: (1) weight (also measured at each IVF/ICSI), (2) exhaled carbon monoxide (CO) used as a tobacco consumption proxy (also measured at each thawed embryo transfer and 24 months after the first IVF/ICSI) (piCO RESPUR MEDICAL, Vauréal, France), (3) scalp hair (the analysis of which will be funded by an ancillary study) from volunteer participants will be collected and banked according to a state-of-the-art protocol [13] and (4) blood samples will be collected to perform lead tests upon risk factor identification or other types of sampling according to specific occupational exposure monitoring. Qualitative lifestyle changes and the effectiveness of interventions proposed by addictologists, dieticians and psychologists, as well as changes in the level of physical activity and daily domestic habits, will be extracted from the four online self-questionnaires completed at enrolment and before the first IVF/ICSI attempt and then every 6 months until 24 months after the first IVF/ICSI. These will be completed with the information collected by protocolized additional interviews when needed, especially regarding occupational exposures. Data analysis plan The methodology and plan of analysis will follow the CONSORT (Consolidated Standards of Reporting Trials Statement) group criteria [68]. All patients will be analysed according to the intention-to-treat principle (ITT). Patients will be assigned to the arm they are randomized into. As a sensitivity analysis, a per-protocol analysis will also be performed. Multiple imputation will be performed as the principal analysis. Complete cases analysis will be performed as a sensitivity analysis. No interim analyses are planned. Population and ART pathway The following population characteristics at enrolment will be obtained: age, infertility duration, infertility type (primary or secondary in the couple), and aetiology, BMI, physical activity, ovarian reserve, semen parameters, lifestyle (addictions and diet), occupation category, occupational and domestic exposures to reprotoxic agents, anxiety and depression, quality of life, health care consumption, intrauterine insemination antecedents in the couple and type of ART prescribed (IVF or ICSI). The total number of embryo transfers and the total number of transferred embryos during the follow-up will be used as adjustment values for the live birth rate. Qualitative variables will be presented as effects and proportions, and quantitative variables will be presented as the means, standard deviations (SDs), minimums, 25th percentiles, medians, 75th percentiles and maximums. For each variable, the proportion of missing data will be precise. The normality of quantitative data will be evaluated via frequency histograms and Shapiro tests; simple mathematical transformations may be used to normalize data. The initial comparability of both arms will be evaluated on all variables available at enrolment. In accordance with CONSORT group principles, no statistical test will be performed to evaluate this initial comparability. Primary endpoint analysis The proportion of couples obtaining at least one live birth during the 24-month follow-up will be compared between arms A and B. The principal analysis will be based on this comparison by using a chi-square test (expected theoretical effectiveness > 5). The choice of this primary endpoint is justified by the objective of couples consulting for ART treatment (which is to become parents) and by the desire to avoid misinterpretation of the cumulative birth rate related to twin pregnancies, which are more frequent after ART treatment than in the general population. A secondary analysis will be performed to take into account possible confounding factors. A multivariate logistic regression model will be used, with the dependent variable of “obtaining at least one live birth during the 24-month follow-up”. The selection of explanatory variables will be based on a univariate approach, which will identify (i) variables for which the degree of significance will be < 0.20 (arm A versus arm B), (ii) variables for which an initial imbalance will be observed despite randomization and (iii) variables potentially associated with live birth. A multivariate logistic regression model forced on the group variable (arm A versus arm B) and on selected explanatory variables will be established. We will estimate the adjusted odds ratios, with their 95% confidence intervals (CIs). Secondary endpoint analysis To analyse the impact of the PREVENIR platform pathway on the biological outcomes of IVF/ICSI, we will compare the following factors in both arms: fertilization rates, transferable embryo rates and embryo implantation rates. The statistical unit for this analysis will be IVF/ICSI. As couples may receive several IVF/ICSI procedures during the study, the couple factor will be considered in the analysis; thus, the correlation that may exist between the biological parameters of IVF/ICSI and the various IVF/ICSI cycles for the same couple will be considered. The principal analysis for these endpoints will be based on performing a univariate linear mixed-effects regression model, in order to estimate the impact of the intervention (arm A) versus the control (arm B), while considering the couple effect. A beta coefficient will be estimated, with its 95% CI. The cumulative rates of clinical and ongoing pregnancies (obtained by ART or spontaneous during the 24-month follow-up) will be compared between arms A and B. The statistical unit considered for this analysis is the couple. The principal analysis for this comparison will be based on using a chi-square test (expected theoretical numbers > 5). The rates of obstetric pathologies and newborn parameters (term, sex, weight, height, major and minor malformations) will be compared in both arms. The statistical unit considered for this analysis is the clinical pregnancy. As couples may have several clinical pregnancies during the study period, the couple factor will be taken into account in the analysis, allowing consideration of the correlation that may exist between clinical pregnancy parameters for the same couple during different possible pregnancies. The principal analysis for these endpoints will be based on performing a univariate mixed-effects regression model (linear for quantitative endpoints, logistic for binary endpoints), in order to estimate the impact of the intervention (arm A) versus the control (arm B), while considering the couple effect. A coefficient will be estimated (beta coefficient for quantitative endpoints, odds ratio for binary endpoints), with its 95% CI. Secondary assessment criteria will also be compared between arms A and B. Behaviour modifications will be assessed through comparisons of self-questionnaire (PREVENIR and IPAQ) responses at each step of the medical pathway—at inclusion, first IVF/ICSI and every 6 months until the end of patient participation. Changes in weight, dietary patterns, physical activity levels, addictions (including expired CO levels) and domestic exposure will be assessed. The HAD and FertiQOL scores will provide data regarding the evolution of the stress evoked by the infertility care pathway and the PREVENIR care pathway. The evolution of lead blood levels will be monitored for risk factor identification. For endpoints measured by quantitative variables, at the start and end of care (toxins, physical activity, diet, stress, protection against reprotoxic exposure), the absolute difference between the start and end of care will be estimated for each participant (end—start), as well as the relative difference [(end—start)/start]. The principal analysis of the impact of the platform’s support on these criteria will be carried out by comparing the absolute and relative differences between the two groups, using Student’s t-test if the conditions of application are met or the Mann–Whitney test otherwise. For all secondary endpoints mentioned above, a complementary analysis will be performed in order to take into account possible confounding factors. A multivariate regression model will be performed for each endpoint, considered as a dependent variable. The selection of explanatory variables will be based on a univariate approach: it will identify (i) variables for which the significance degree will be < 0.20 (arm A versus arm B), as well as variables for which an initial unbalance will be observed despite randomization, and (ii) variables potentially associated with the considered endpoint. A multivariate regression model (linear for quantitative endpoints, logistic for binary endpoints), forced on the group variable (arm A versus arm B) and on selected explanatory variables, will be established. We will estimate adjusted coefficients (beta coefficients for quantitative endpoints, odds ratios for binary endpoints), with their 95% CI. Health economic analysis A cost-effectiveness analysis will be performed, which will involve calculating an incremental cost-effectiveness ratio expressing the additional cost of the platform per unit of additional efficacy obtained compared with standard care. The efficacy criterion used will be similar to the primary endpoint of the PREVENIR-IVF study, i.e. the proportion of couples achieving at least one live birth within 24 months. The ratio will express the additional cost per additional live birth. The health economic analysis will be conducted over the time horizon of the trial (24 months), and the collective perspective will be considered. Direct costs will be compared, including the costs of the platform management, specialist consultations and biological tests, ART treatment, complications management, outpatient visits, medications, examinations, any hospital admissions for childbirth or related conditions as well as transport. Resource use will be collected by linkage with the French nationwide healthcare data system (SNDS) database, which offers a comprehensive overview of all reimbursed medical and paramedical resource consumption for each individual with social security. Productivity losses will be collected using patient questionnaires and compared between the two arms. Production costs diagnostic-related group from ENCC will be used for inpatient costs. For outpatient costs, national reference prices will be used. Deterministic and probabilistic sensitivity analysis will be performed to identify thresholds for factors influencing the cost-effectiveness ratio, and a cost-effectiveness acceptability curve will be provided. For the budget impact analysis, an implementation and dissemination model (i.e. construction of scenarios) will be built from the data collected in the trial, including costs and savings for the healthcare system, and will be fed by hypotheses on the size of the target population and the rate of penetration of the innovative platform into the practice. No audit of trial conduct is planned for this study. However, regular on-site monitoring visits are conducted to ensure data quality control, compliance with the protocol, and the safety and well-being of the patients. These visits also help identify any potential non-compliance issues, monitor the progress of the study, and ensure the integrity of the collected data. Important protocol modifications will be decided and validated by the steering committee of the project, submitted to the Committee for Protection of Persons (CPP), and, after acceptance, communicated to relevant parties by the principal investigators of each centre and by the coordination of the project. Ethics and dissemination The study will be performed in accordance with the Declaration of Helsinki and monitored following the sponsor’s standard operating procedures. Written informed consent will be obtained from each participant prior to study enrolment. Data will be entered into a dedicated e-CRF (online study notebook) (REDCap, CleanWeb; Telemedicine Technologies, Boulogne-Billancourt, France). The trial was registered at ClinicalTrials.gov (identifier no. NCT de PREVENIR-IVF NCT06100523). The level of monitoring to be set up in this research will be intermediate. The following points will be monitored: (1) Existence of included patients, (2) signed informed consent form, (3) eligibility criteria, (4) secondary criteria, (5) side effects (e.g. serious side effects, tolerance, and new facts), (6) compliance with the monitoring schedule and (7) data monitoring according to the monitoring guide implemented. The protocol provides for the possibility to build a bank of hair samples. Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies will be asked for. Patients agreeing for hair sampling will sign a consent for biobanking and subsequent use of the sample for research purposes. Each centre will use the consent of its biobank, and the research team will ensure that the various consent forms used by each biobank cover the exact same provisions for future research. Personal data of potential and enrolled participants will be processed in strict compliance with the General Data Protection Regulation (GDPR) and Good Clinical Practice (GCP) guidelines. Before the study: Personal data collected during the pre-inclusion process (e.g. initials, date of birth, eligibility criteria) will be obtained by authorized healthcare professionals directly from the medical records. This information will remain confidential and accessible only to members of the research team involved in participant screening.During the study: Upon inclusion, data will be pseudonymized. Each participant will be identified by a unique study code. The correspondence between this code and the participant’s identity (the identification key) will be stored securely and separately from the study data, accessible only to the principal investigator or authorized staff. No document sent to the sponsor will contain any directly identifying information.After the study: Data will be retained for the legally required period under conditions that ensure their security and confidentiality (secure archiving, restricted access). The data will remain pseudonymized. Any publication or communication of results will be done in a fully anonymized manner. Before the study: Personal data collected during the pre-inclusion process (e.g. initials, date of birth, eligibility criteria) will be obtained by authorized healthcare professionals directly from the medical records. This information will remain confidential and accessible only to members of the research team involved in participant screening. Before the study: Personal data collected during the pre-inclusion process (e.g. initials, date of birth, eligibility criteria) will be obtained by authorized healthcare professionals directly from the medical records. This information will remain confidential and accessible only to members of the research team involved in participant screening. During the study: Upon inclusion, data will be pseudonymized. Each participant will be identified by a unique study code. The correspondence between this code and the participant’s identity (the identification key) will be stored securely and separately from the study data, accessible only to the principal investigator or authorized staff. No document sent to the sponsor will contain any directly identifying information.After the study: Data will be retained for the legally required period under conditions that ensure their security and confidentiality (secure archiving, restricted access). The data will remain pseudonymized. Any publication or communication of results will be done in a fully anonymized manner. During the study: Upon inclusion, data will be pseudonymized. Each participant will be identified by a unique study code. The correspondence between this code and the participant’s identity (the identification key) will be stored securely and separately from the study data, accessible only to the principal investigator or authorized staff. No document sent to the sponsor will contain any directly identifying information.After the study: Data will be retained for the legally required period under conditions that ensure their security and confidentiality (secure archiving, restricted access). The data will remain pseudonymized. Any publication or communication of results will be done in a fully anonymized manner. After the study: Data will be retained for the legally required period under conditions that ensure their security and confidentiality (secure archiving, restricted access). The data will remain pseudonymized. Any publication or communication of results will be done in a fully anonymized manner. After the study: Data will be retained for the legally required period under conditions that ensure their security and confidentiality (secure archiving, restricted access). The data will remain pseudonymized. Any publication or communication of results will be done in a fully anonymized manner. All data processing is conducted in accordance with applicable data protection regulations and, if applicable, under a CNIL declaration or MR001/MR003 compliance. Participants (or their legal representatives) will be informed of their rights (access, rectification, objection, etc.) in the participant information sheet. Oversight and monitoring Steering committee is composed of the principal investigator of the project (Jeanne Perrin), the team in charge of the project in University Hospitals of Marseille (Claire Sunyach, PREVENIR platform coordination; Blandine Courbiere, clinical centre of assisted reproductive treatments; Nicolas Simon., addictologist; Sandrine Loubiere and Noémie Resseguier, clinical research department; Claire Morando, project manager; and Lola Moreau), and the principal investigators of each centre involved in the project (Fleur Delva, Ronan Galrlantezec, Roger LEANDRI, Nathalie Rives, Vanessa Lubin, Maud Pasquier). It is responsible for the proper development and promotion of the study. It will meet at the launch of the project, the validation of the data collection documents, for the drafting of the protocol, during the evaluations of the progress of the project (each 6 months after the launch) and for the drafting of the publications. Data management team is composed of Yasmine Hamdi and Richard Malkoun (Clinical Research Department of University Hospitals of Marseille). Data managers and principal investigators will have access to the final trial dataset. Trial results will be communicated to participants on demand and to healthcare professionals and the public via scientific publications in peer-reviewed journals. Authorship eligibility will follow the ICMJE guidelines. No professional writers will be used. Valorization will be published in open access (including the protocol), and the data set will be available on reasonable demand upon the principal investigator. Discussion Multiple lifestyle factors and exposure to environmental reprotoxic agents can affect the fertility and pregnancy rates of couples after assisted reproductive technique (ART) treatment [20, 56, 62, 63]. Nevertheless, such exposures are generally poorly assessed in current practice during the diagnostic phase before ART. Importantly, men are generally less aware of their exposure to reprotoxic factors [52], and the exposure of men to reprotoxic factors is researched less than that of women. In addition, neither the public nor health professionals in the field of reproductive medicine are fully ready to consider occupational exposure. However, literature regarding the impacts of physical, chemical and stress at work on fertility and pregnancy is available ([4, 42, 63, 74]). Therefore, there is a need to inform couples to avoid exposure to reproductive risk factors. However, only a few studies have reported efficient interventions that consider a limited number of reprotoxic factors. The PREVENIR-IVF protocol will address these lifestyle and environmental exposures in a holistic way, with a strong focus on occupational exposures. The PREVENIR-IVF project may provide holistic proactive recommendations for physicians and specialists aimed at (1) addiction weaning, (2) weight loss, (3) Mediterranean dietary adhesion, (4) increased physical activity, (5) decreased stress, (6) prevention of occupational reprotoxic exposure and (7) mitigation of domestic exposure to EDs to enhance birth rate (either spontaneously or after ART treatment). A shortened time to pregnancy could be obtained. Importantly, the project includes a medicoeconomic evaluation of this new care pathway. Subfertile couples together with health care professionals should be more proactive in making and promoting lifestyle changes. The following factors should be targeted to help patients conceive: toxicants (tobacco, cannabis, alcohol and other drugs), diet, physical activity, stress, workplace conditions and domestic habits leading to ED exposures. Health professionals of the PREVENIR platforms will propose tailored care pathways addressing pertinent environmental factor(s) for each patient. Addressing several environmental factors can be difficult. Hopefully, TCSs and the specially designed health application will enhance adherence to patient–health professional alliances. TCS will spare time and travel, and it will also provide the same quality of care for patients regardless of the centre in which they have been enrolled, as the same dietician, addictologist and psychologist team will be in charge throughout the country. This design should make the ART pathway easier by reducing professional absenteeism and should improve compliance for specialized monitorings. In addition, information and counselling provided during the PREVENIR-improved ART pathway will contribute to the empowerment of patients. A strength and originality of the PREVENIR-IVF study is the management of occupational reprotoxic exposures. Indeed, occupational exposures are characterized by chronic, repetitive and prolonged exposure and by exposure levels that can exceed those encountered in household circumstances. The characterization of these exposures requires specific skills not mastered by reproductive medicine specialists, who express “scarce knowledge and […] lack of solutions” about these questions [66]. The participation of occupational and public health physicians in the PREVENIR platforms is allowed by the association with French regional centres for occupational and environmental pathologies [21, 22]. These centres are expert recourse structures for the management of complex occupational pathologies: they provide a specialized system of advice and assistance in researching the origin and occupational cause of observed pathologies and also contribute to the prevention of occupational pathologies. In the PREVENIR-IVF study, when occupational reprotoxic exposures are suspected in arm “platform” by answers to the self-questionnaire assessing environmental exposures (supplementary data 1), the platform practitioners will use a specialized interview guide (supplementary data 2) in order to precisely characterize reprotoxic exposures. Safety data sheets of chemical products related to occupational exposures will be analysed if necessary. This interview guide was developed by the occupational and public health physicians of the project: the information obtained in this interview will be used in the multidisciplinary consultation meeting for personalized counselling of the patients and may induce for the patient a teleconsultation with the occupational physician of the platform. Another strength of the project is the PREVENIR network, which has developed shared expertise, mutualized tools (questionnaires, template reports and interview guidelines) and unified counselling since its inception in 2017. The project has several flaws. Few exposure biomarkers (exhaled CO measurement, blood lead concentration and possible targeted biomarkers related to occupational exposures) will be used. In addition, contamination bias cannot be excluded, as four teams participating in the study have already proposed counselling to reduce occupational and domestic exposures. Randomization by centre rather than by patient may have alleviated this pitfall but was unacceptable for centres in which specialized visits were set up for several years. Perspectives Infertility and decreased fecundity are important issues at both the individual and societal levels, with significant repercussions for family health and health care systems. As an increasing number of couples rely on ART for reproduction, efforts should be made to improve the live birth rate after ART. In addition to improving technology and medical progress, there is room for holistic intervention in behaviour, occupational environments and domestic environments to prevent and mitigate reprotoxic exposure. The PREVENIR-IVF project will evaluate for the first time the impact of the multidisciplinary platform network’s care for subfertile couples on the chances of a live birth in ART. Environmental issues affect not only fertility but also the course of pregnancy and the health of the unborn child and the family at large. A better appreciation of environmental risk factors and their consideration at the start of the ART process will need to be pursued in collaboration with obstetricians throughout pregnancy and with paediatricians. This is an important issue in view of the concept of developmental origins of health and disease (DOHaD), which is gradually gaining ground in the scientific and medical community [38]. Current evidence indicates that unhealthy inappropriate preconceptional diets and lifestyles in both men and women not only contribute to impaired reproduction with potential long-term consequences for parental health but also compromise the health of offspring [32, 45]. From a public health and social point of view, professional health networks such as PREVENIR would contribute to health education by raising awareness of the environmental challenges to reproductive health. On the basis of the data and samples collected by the PREVENIR-IVF project, the ancillary study ECHO (not yet funded) will use hair analysis to provide biomarkers of environmental exposure to the reprotoxins most frequently encountered in subfertile couples, namely, endocrine disruptors (EDs), tobacco, cannabis and pesticides. Trial status Protocol version number 4 (Nov 7th, 2024, No. IDRCB 2022-A01017-36). Recruitment began on Oct 15, 2024, and should be completed at the end of 2026. Supplementary Information Supplementary Material 1. Data 1. Questionnaire.Supplementary Material 2.Supplementary Material 3. Annex 1. Consent and Information.Supplementary Material 4. SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents. Supplementary Material 1. Data 1. Questionnaire. Supplementary Material 2. Supplementary Material 3. Annex 1. Consent and Information. Supplementary Material 4. SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents.